Apr 18, 2022 · 48m · neon-show
Building A 180 CRORE Women Nutrition Brand! ft. Aarti Gill, Co-Founder, OZiva
0:00 / 0:00
▶ Watch on YouTube →
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
In this in-depth interview, OZiva co-founder Aarti Gill details how she built a 180-crore clean, plant-based nutrition brand through disciplined bootstrapping, scientific product innovation, and bold omni-channel brand building.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. How this is scored →
Siddhartha as informed peer 3.0 Guest teaching 3.6 Guest disagreement 0.4 Siddhartha pushing back 1.4
speaking balance: gold is Siddhartha, purple is the guest (3 minute bins)
Sharpest disagreement ▶ 46:32 Aarti rejects the narrow nutrition category boundary
Aarti firmly counters the host's doubt about branching outside nutrition, arguing that solving skin or hair health necessitates both inside-out consumption and topical application.
Hardest push from Siddhartha ▶ 46:19 Host questions expanding beyond the core nutrition moatSiddharth presses Aarti on why the company diluted its focus into topical beauty rather than deploying capital exclusively to dominate nutrition categories.
Biggest teaching moment ▶ 31:42 Aarti breaks down adult supplement consumer psychologyAarti educates the host on the low repeat purchase reality in adult nutrition (2 boxes/year) compared to kids nutrition, showing why cross-selling is essential.
Siddhartha holds their own ▶ 9:43 Host highlights omnichannel distribution barriersSiddharth demonstrates sector knowledge by challenging Aarti on how tough offline omnichannel scaling is without the massive distribution armies of Unilever or P&G.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | Siddhartha as informed peer | Guest teaching | Guest disagreement | Siddhartha pushing back | Why |
|---|---|---|---|---|---|---|
| Introducing Aarti Gill and the Vision Behind OZiva | 2 | 3 | 0 | 0 | The host warmly introduces Aarti Gill and sets the context for Oziva. Aarti details top-level revenue metrics (150-180 Cr), CAGR, and core products addressing nutritional gaps like PCOS. | |
| Navigating Retail Rejections to Build an Omni-Channel Brand | 4 | 4 | 1 | 3 | Siddharth challenges the choice to go omnichannel early on, noting it usually requires Unilever or P&G scale distribution armies. Aarti clarifies that retail rejection initially forced them online, but omnichannel remains essential as customer fulfillment. | |
| Aarti Gill's Roots, Education, and Passion for Preventive Healthcare | 1 | 2 | 0 | 0 | A straightforward biographical section where Aarti discusses growing up inspired by her mother in healthcare, graduating from IIT Roorkee and INSEAD, and returning to India for preventive health. | |
| From FitCircle Consultations to Formulating Clean Plant Nutrition | 2 | 4 | 0 | 0 | Aarti explains how FitCircle consultations revealed that busy professionals could not stick to strict meal plans, and existing supplements contained harmful additives, prompting them to formulate clean nutrition products. | |
| Product-Market Fit and Solving the Price Point Challenge | 3 | 4 | 0 | 1 | Aarti shares the learning curve of product pricing, explaining that cramming every beneficial ingredient into one product created a prohibitive 1400 INR price tag, requiring them to unbundle into specific 500-900 INR price points. | |
| Enhancing Customer Lifetime Value Through OZiva Prime | 3 | 3 | 0 | 1 | Host inquires about capital allocation and VC fundraising. Aarti explains repurposing FitCircle services into Oziva Prime to bolster LTV/retention and relying on internal accruals and bank debt before institutional equity. | |
| Scaling from a Living Room Office to 20 Crores Revenue | 3 | 3 | 0 | 1 | Aarti describes scaling the business from her Mumbai living room to 20 Crores revenue with high SKU concentration in top sellers like PCOS hormonal balance products. | |
| Marketing Shifts and Rapid Acceleration from 20 to 100 Crores | 3 | 4 | 1 | 2 | The discussion turns to marketing efficiency. Aarti explains the transition from cheap early performance marketing on Meta/Google to long-term brand equity and tailwinds from post-COVID health awareness. | |
| Cracking Adult Nutrition Retention and the 500-Crore Roadmap | 4 | 5 | 1 | 2 | Aarti schools the host on the structural hurdles of adult nutrition retention, explaining that adults only buy reactive supplements twice a year, requiring cross-selling and HCP validation to build a 500 Cr brand. | |
| Investor Discovery and Valuation Mental Models | 4 | 3 | 1 | 2 | Siddharth probes whether remaining undiscovered by VCs until Titan and Matrix was an intentional strategy and asks about valuation revenue multiples. Aarti explains paper multiples matter far less than long-term partner alignment. | |
| Deepika Padukone Brand Campaign and Media Execution | 3 | 4 | 0 | 2 | Host explores the decision to sign Deepika Padukone despite historical frugality. Aarti outlines how large brand bets place Oziva alongside legacy names like Horlicks and Protinex, testing creatively on digital before scaling via TV. | |
| Clean Beauty Expansion and Final Takeaways | 4 | 4 | 1 | 3 | Host questions why Oziva expanded into clean beauty rather than doubling down solely on nutrition. Aarti explains that hair and skin issues require both consumable and topical solutions to build effective daily routines. |
Statements from this episode (22)
Swamy: Indian startups now hit $5M-$10M revenue in 12-18 months
“10 years ago, you know, getting to five, ten million dollars of revenue was itself a big achievement, but now we're seeing that happening, you know, in 12 to 18 months in some cases.”
Swamy: Western, Chinese, and Israeli business models cannot solve India's problems
“Western models, the Chinese models, the Israeli models are not what's going to solve India's problems.”
Gill: OZiva filed patents for novel plant-derived calcium and iron
“Today we filed patterns and we have, you know, IP for some of these newer ingredients that we have derived. Right. Whether it being a calcium from a plant source or iron from a plant source.”
Gill: OZiva hit ₹150-180 crore revenue with a 140% 3-year CAGR
“Today, you know, we are predominantly sitting at between 150 to 180 CR, right? Our growth for the last three years, we've grown at a one 40% CAGR and I think over the last three, four years, 2.5 million people or 25 black people have used our products”
Gill: Nearly 90% of offline retailers rejected OZiva at launch
“When we launched the brand, right. We actually went to offline initially, and we were rejected by, obviously, almost 90% of the retailers out there that you will keep your product, which is a typical story”
Gill: D2C websites and retail should be treated simply as fulfillment channels
“Even today, I look at my own D to C as a fulfillment channel, e-commerce as a fulfillment channel, and also a chemist as a fulfillment channel. If a person wants a chemist, he can buy it from there. If they buy it from Amazon or Flipkart, the product should be…”
Gill: 1 in 4 women consulting OZiva reported having PCOS
“Because a lot of women who came on a platform and consulted with us said like, you know, one out of four said like, I have PCOS and we realized that there is no solution that is talking to them.”
Gill: Clean eating trends are adopted first by women globally
“Also, globally, what we realized was that, you know you know, clean eating as a concept, right, is, is a lot first adopted by women and In, in the global or in the Western market as well, which is where we saw the same kind of trend in India as well, right?”
Gill: OZiva unbundled multi-benefit formulas to slash prices to ₹500-₹900
“Thereafter, the product lines that we built was, each problem became a separate solution, right? Rather than trying to merge these three, four kind of problems together, because the price points became too more expensive, right? So hence, our next price points…”
Gill: OZiva Prime nutritionist consultations boosted retention and lifetime value
“And I think that's the service today, which we focused on. How do we and it has helped us to improve our retention rates, right? Our LTVs.”
Gill: Founders should only raise capital after achieving product-market fit
“Both Mihir and I believe that you should raise capital when your business problem is solved, when you have a product market fit, because that's when you will be able to do justice to that capital. Right. Otherwise it's just gonna go, you know, it would be wast…”
Gill: OZiva was profitable early on with 5 home-based employees
“So we were operating with five, six people working from my home, right? In the initial two, three years through the limited capital that we had, right? We were growing based on that by, you know, and we were profitable in the first, obviously few years of our …”
Gill: OZiva's D2C site drove 40% to 50% of its early sales
“We've been very strong digital first, right, for the first five years of our journey as well, and where the distribution was happening mainly through our own platform, which was contributing around 40 to 45 or 50% of our sales, right, and the rest was coming f…”
Gill: 90% of OZiva's marketplace buyers searched for branded keywords
“Was that even if people are buying on the e-commerce platforms, they were searching for, say, 90% of them were searching for Oziva branded keyword, right? So people are looking up, looking for Oziva Herbalance, Oziva Protein, right?”
Gill: Scaled adult nutrition brands see max two repeat boxes yearly
“I think the age group between, I would say, 25 to 45 or 50, right? Where, which is where the retentions are not that great. Right. Where say even scaled up brands have seen maximum two boxes in an year being picked up.”
Gill: There has been zero innovation in Indian OTC over 10 years
“Because I think in the last 10 years, there has been zero innovation in the OTC space, right?”
Gill: 20% of OZiva customers drop out after consulting uninformed doctors
“We saw that 20% of our people drop out because, you know, they go to a HCP and they say, I can take this regularly and not, right? And the HCP says, I don't know, I'm never, or, you know, I'm not sure.”
Gill: D2C company revenue valuation multiples generally range between 4x and 8x
“I think that is pretty much set by the, you know, it's general in the industry. It could be anywhere between say four to Seven or eight X also, which is then based on how good the unit economics of the business are. Right. What is the potential of growth, righ…”
Gill: Private valuations are paper; true value is realized at listing
“I think in a, you know, because these are intermediate valuations, right? These are paper valuations. How much do they matter? I think your ultimate story comes in when you actually get listed, right? In general, I think that's the way to identify or say, for …”
Gill: Digital tests creative concepts while scaled TV delivers cheaper reach
“I think the digital gives you a good way to experiment on your creative cons. And then if you think that it's working well, then you can actually take it to a much larger kind of a reach, right? And I think TV on a large scale turns out to be much cheaper way …”